4
Oct 2 (Reuters) – FDA: * FDA APPROVES LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER- WEBSITE Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)